JPRN-jRCTs031180083进行中（未招募）3 期
JCOG1308C: A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab - RE-GEND-pIII
AGANE Motoo0 个研究点目标入组 146 人开始时间: 2019年1月17日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven diagnosis of glioblastoma (including giant cell glioblastoma and gliosarcoma) by WHO2007 criteria.
- •2) For patients who did not undergo surgery for recurrent disease; pre-registration contrast MRI should confirm;
- •(i)progressive or recurrent glioblastoma; (ii)no evidence of acute or subacute cerebral hemorrhage at enrolment; (iii)presence of a measurable lesion.
- •3) For patients who underwent surgery for recurrent disease;
- •(i)progressive or recurrent glioblastoma diagnosed with WHO2007 criteria must be confirmed on contrast MRI before reoperation; (ii)glioblastoma or anaplastic astrocytoma diagnosed with WHO2007 criteria must be histologically identified in the tissue resected at reoperation; (iii)presence of measurable lesions is not mandatory on pre-registration contrast MRI (more than 14 days after reoperation, within 14 days before enrolment ); (iv)no MRI evidence of aggravating cerebral hemorrhage.
- •4) No evidence of tumors in the cerebellum, brain stem, optic nerve, olfactory nerve, and pituitary gland.
- •5) No evidence of meningeal dissemination or gliomatosis cerebri.
- •6) Prior treatment for newly-diagnosed glioblastoma (or diffuse astrocytoma (Grade II) or anaplastic astrocytoma (Grade III)) with postoperative TMZ administered concomitantly with radiotherapy (>=54 Gy for <=69 years old; >=30 Gy for >=70 years old) and at least for two cycles (5/28d) as an adjuvant treatment have been given.
- •7) No history of prior treatment with stereotactic radiotherapy (ex. Gamma-knife/Cyberknife), proton beam irradiation, neutron capture therapy, and chemotherapies except standard dose TMZ and immunotherapy (vaccines, immune checkpoint inhibitors, antibodies etc.), bevacizumab (12 weeks or more after termination of prior upfront bevacizumab use) that were combined with TMZ, and intraoperative placement of carmustine wafers for glioblastoma (including diffuse astrocytoma (Grade II) and anaplastic astrocytoma (Grade III) at onset) diagnosed with WHO2007 criteria. Time periods required from the last day of the prior treatment indicated at registration.
- •(i) Peptide vaccination, immune checkpoint inhibitors, antibodies: 4 weeks.
- •(ii) Bevacizumab: 12 weeks.
- •8) More than 90 days after completion of radiotherapy. For those who underwent reoperation, between 21 and 28 days postoperatively.
- •9) Age between 20 and 75 years at enrolment.
- •10) KPS >= 60 within 14 days before enrolment.
- •11) No prior treatment with chemotherapy, molecular targeted therapy, or radiotherapy to head and neck area for other malignancies.
- •12) Adequate organ function.
- •13) Written informed consent.
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy
- •2) Active infection requiring systemic therapy
- •3) Body temperature >= 38 degrees Celsius at registration
- •4) Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding
- •5) Psychosis or with psychotic symptom
- •6) Continuous systemic use of immunosuppressant except for steroid
- •7) Uncontrolled diabetes mellitus
- •8) Unstable angina within 3 weeks, with a history of myocardial infarction within 6 months, or New York Heart Association (NYHA) class II or greater congestive heart failure
- •9) Inadequately controlled hypertension (cannot be controlled to a systolic pressure of >= 150 mmHg and a diastolic pressure of >= 100 mmHg)
- •10) History of symptomatic cerebrovascular disorder (including subarachnoid hemorrhage, cerebral infarction and transient ischemic attack) within 6 months or history of vascular disorder requiring intervention (including venous/arterial thrombosis or embolism and aortic aneurysm) within 6 moths
- •11) History of grade >= 2 hemoptysis within 28 days
- •12) History of hemorrhagic tendency (e.g., coagulation disorder) or any grade >= 3 hemorrhage within 28 days
- •13) History of gastrointestinal perforation, fistula, abdominal abscess or uncontrolled peptic ulcer within 6 months
- •14) Interstitial pneumonia, pulmonary fibrosis, or severe lung emphysema
- •15) Severe non-healing wound or traumatic fracture at enrolment
- •16) Hypersensitivity to CHO-derived drugs or other recombinant antibodies
- •17) Gadolinium allergy
- •18) Positive HIV antibody
- •19) Positive HBs antigen
研究者
相似试验
招募中
3 期
JCOG2108: A multicenter randomized phase III study of systemic chemotherapy followed by maintenance therapy versus local consolidation therapy for postoperative oligometastatic recurrent non-small cell lung cancerJPRN-jRCTs031230475Watanabe Shun-ichi200
进行中（未招募）
3 期
JCOG1703: A multicenter randomized phase III study for newly-diagnosed maximally resected glioblastoma comparing Carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy aloneglioblastomaJPRN-jRCT1031190035KUMABE Toshihiro250
进行中（未招募）
3 期
JCOG2007: A Multicenter Randomized Phase III Study comparing Pembrolizumab + Platinum Combination Chemotherapy with Nivolumab + Ipilimumab + Platinum Combination Chemotherapy for Treatment-naive Advanced Non-Small Cell Lung Cancer without Driver Gene alteratioTreatment-naive advanced non-small cell lung cancer without driver gene alterationNSCLC, advanced, driver oncogene negativeD002289JPRN-jRCTs031210013OKAMOTO Isamu422
进行中（未招募）
3 期
JCOG1314: A randomized controlled phase III study comparing docetaxel, CDDP and 5-FU with CDDP and 5-FU in patients with metastatic or recurrent esophageal canceresophageal cancerJPRN-jRCTs031180143TSUBOSA Yasuhiro240
招募中
3 期
JCOG2013: A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: a phase 3 trialEsophageal cancerJPRN-jRCT1030220248Tsubosa Yasuhiro480